- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | EQL Pharma AB: Year-end Report April 2025 - March 2026 | 151 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 120.2 million, an increase of 6% from SEK 113.3 million in the previous year. Growth for next year negatively impacted by launch delays, but long-term outlook unchanged.
Comments... ► Artikel lesen | |
| 27.04. | EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO) | 6 | Cision News | ||
| 22.04. | Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26 | 1 | Cision News | ||
| 27.03. | EQL Pharma AB: EQL Pharma CEO sells shares to finance capital gains tax from option redemption | 149 | GlobeNewswire (Europe) | EQL Pharma CEO Axel Schörling has recently sold shares for approximately SEK 1.2 million to finance capital gains tax that arose upon redemption of the option program in September 2025.
Axel Schörling... ► Artikel lesen | |
| 25.03. | EQL Pharma AB: Mellozzan (melatonin) has been approved in Italy | 120 | GlobeNewswire (Europe) | EQL's key product Mellozzan® has now received Marketing Authorization approval from the health authority in Italy (AIFA), where it will be provided to patients by EQL's licensing partner Italfarmaco... ► Artikel lesen | |
| EQL PHARMA Aktie jetzt für 0€ handeln | |||||
| 12.02. | EQL PHARMA AB: Nomination committee for the 2026 Annual General Meeting | 1 | Cision News | ||
| 03.02. | EQL Pharma AB: Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026 | 185 | GlobeNewswire (Europe) | Today, on 3 February 2026, the extraordinary general meeting was held in EQL Pharma AB. A summary of the adopted resolution follows below.
Resolution on implementation of a long-term incentive program... ► Artikel lesen | |
| 03.02. | EQL Pharma AB: Interim Report April - December 2025 | 170 | GlobeNewswire (Europe) | During the quarter, sales rose to SEK 118.9 million, an increase of 29% from SEK 92.2 million in the previous year. This represents a new record quarter for EQL
Comments from the CEO
The third quarter... ► Artikel lesen | |
| 15.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26 | 3 | Cision News | ||
| 07.01. | Notice of extraordinary general meeting in EQL Pharma AB | 1 | Cision News | ||
| 04.12.25 | EQL Pharma AB: EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO) | 344 | GlobeNewswire (Europe) | As previously announced, EQL Pharma has decided to strengthen its abilities in international commercial affairs, as a part of its European expansion. The Company has recruited Anne D. Jensen for this... ► Artikel lesen | |
| 03.12.25 | EQL Pharma AB: EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO) | 179 | GlobeNewswire (Europe) | EQL Pharma strengthens and re-organizes its Finance Function to put more emphasis on business control and capital allocation. Our current CFO, Anna Jönsson, will take on the role as Head of Accounting.... ► Artikel lesen | |
| 14.11.25 | EQL Pharma AB: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany | 850 | GlobeNewswire (Europe) | EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in Germany, where it is to be provided to patients by EQL's license partner Dr Pfleger under the EQL... ► Artikel lesen | |
| 05.11.25 | EQL Pharma AB: Interim Report April - September 2025 | 186 | GlobeNewswire (Europe) | A tough quarter for EQL
Comments from the CEO
The second quarter of 2025/26 was marked by unforeseen delivery disruptions, resulting in sales growth of only 1%. The EBITDA margin, which was naturally... ► Artikel lesen | |
| 06.10.25 | EQL Pharma AB: EQL Pharma in process of recruiting new Chief Commercial Officer (CCO) | 205 | GlobeNewswire (Europe) | EQL Pharma is recruiting a new CCO with an international background as part of its new five-year plan. This means that the current Chief Commercial Officer (CCO) Alexander Brising will leave his position.... ► Artikel lesen | |
| 22.09.25 | EQL Pharma AB: Delivery delays mean that the second quarter and thus the full year 2025/26 will be weaker than expected | 331 | GlobeNewswire (Europe) | EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made... ► Artikel lesen | |
| 25.08.25 | EQL Pharma AB: EQL Pharma's Chief Commercial Officer (CCO) sells shares to buy apartment for daughter | 246 | GlobeNewswire (Europe) | EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a decision... ► Artikel lesen | |
| 21.08.25 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025 | 275 | GlobeNewswire (Europe) | Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
| 08.08.25 | EQL Pharma AB: Interim Report April - June 2025 | 476 | GlobeNewswire (Europe) | A strong start to the year - Sales and operating profit growing, good progress in business development
April - June 2025
Consolidated sales during the first quarter, April to June amounted to SEK... ► Artikel lesen | |
| 08.07.25 | EQL Pharma AB: EQL takes first step to establish itself in Germany and the Netherlands | 210 | GlobeNewswire (Europe) | EQL has now taken the first step to establish itself in Germany and the Netherlands by recruiting key people with knowledge of the local markets who can identify, develop/in-license and launch niche... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 375,95 | -0,27 % | Vertex: FDA Accepts BLA Submission For Povetacicept; Assigns PDUFA Target Action Date Of Nov. 30 | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has accepted its Biologics License Application submission for povetacicept, an investigational... ► Artikel lesen | |
| UNITED THERAPEUTICS | 469,70 | +0,28 % | United Therapeutics Corp Q1 Income Declines | WASHINGTON (dpa-AFX) - United Therapeutics Corp (UTHR) released a profit for first quarter that Dropped, from last yearThe company's bottom line came in at $274.9 million, or $5.82 per share.... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 26,900 | 0,00 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| INDIVIOR PHARMACEUTICALS | 30,000 | -0,66 % | Indivior Pharmaceuticals Inc.: Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results | Generated Record Quarterly and Full-Year Total SUBLOCADE Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly... ► Artikel lesen | |
| CAMURUS | 51,45 | +0,68 % | Eli Lilly: Es geht Schlag auf Schlag - nächster Deal mit Camurus | Der US-amerikanische Pharma-Riese Eli Lilly bleibt auf Shopping-Tour. Neben zwei Lizenzdeals in Asien konnte das Unternehmen auch eine erweiterte Partnerschaft mit der schwedischen Camurus einfädeln.... ► Artikel lesen | |
| BAYER | 33,330 | -5,12 % | Bayer-Aktie: Das könnte brandgefährlich werden | Die Bayer-Aktie pendelte in den letzten drei Monaten in einem Seitwärtstrend zwischen 36 und 41 € auf und ab. Doch nun könnte eine Nachricht die Aktie aus diesem Trend nach unten reißen. Wie sollten... ► Artikel lesen | |
| MERCK KGAA | 130,75 | 0,00 % | DAX-Check LIVE: Delivery Hero, Infineon, Merck, Nordex, Secunet, Siemens im Fokus | Der deutsche Aktienmarkt hat den Pfingstmontag mit einem fulminanten Kurssprung begangen. Der DAX startete mit Gewinnen, übersprang direkt die wichtige Marke von 25.000 Punkten und kletterte im Verlauf... ► Artikel lesen | |
| NOVO NORDISK | 37,670 | -1,26 % | Vorsicht bei BioNTech! Novo Nordisk gibt Gas! Kaufchance bei Vidac Pharma Aktie! | Kaufstimmung bei Novo Nordisk. Die Aktie des dänischen Pharmagiganten scheint den seit Sommer 2024 begonnenen Abwärtstrend zu verlassen. Anleger reagieren auf positive Meldungen. Bei Vidac Pharma ist... ► Artikel lesen | |
| PFIZER | 22,020 | -0,07 % | Pfizer: Gedämpfte Erwartungen in der Krebsforschung lasten auf der Aktie | Pfizer bleibt unter Druck, denn Barclays sieht trotz laufender Krebsstudien kaum Chancen auf eine Kursrally. Die Analysten halten das Potenzial der Onkologie-Pipeline für begrenzt und bestätigen ihr... ► Artikel lesen | |
| ELI LILLY | 929,40 | -0,10 % | HBM Healthcare Investments AG: Eli Lilly übernimmt HBM-Portfoliounternehmen Curevo für bis zu USD 1.5 Milliarden | HBM Healthcare Investments AG
/ Schlagwort(e): Ankauf
Eli Lilly übernimmt HBM-Portfoliounternehmen Curevo für bis zu USD 1.5 Milliarden
26.05.2026 / 13:10 CET/CEST
Die... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 81,47 | +0,56 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 28,680 | 0,00 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,970 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| NOVARTIS | 125,94 | +0,27 % | Mesoblast: Während Amgen und Novo Nordisk den Biotech-Hype treiben, arbeitet dieser Zelltherapie-Player am operativen Durchbruch | ||
| ABBOTT LABORATORIES | 75,46 | +0,05 % | EQS-News: Abbott erhält CE-Kennzeichnung für die weltweit erste duale Glukose-Keton-Sensortechnologie für Menschen mit Diabetes | EQS-News: Abbott
/ Schlagwort(e): Expansion/Sonstiges
Abbott erhält CE-Kennzeichnung für die weltweit erste duale Glukose-Keton-Sensortechnologie für Menschen mit Diabetes
27.05.2026... ► Artikel lesen |
EQL PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,170 (-7,42 %) liegt der Kurs bei 2,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EQL PHARMA AB finden Sie auf Wallstreet Online.